Patients with chronic intractable dizziness (henceforth referred to as “intractable dizziness”) have a high risk of developing frailty complications. This warrants investigation of a combined treatment for intractable dizziness and frailty. Ninjin'yoeito (NYT), a traditional Japanese medicine (Kampo medicine), is reportedly effective in treating frailty and sarcopenia. Herein, we report on the results of a retrospective study that involved the combined application of NYT and dizziness rehabilitation therapy (henceforth referred to as “dizziness rehabilitation”). Of the 31 patients with intractable dizziness, 14 developed frailty, indicating a complication rate of 45.2%. This in turn was approximately 4 times higher than the previously reported rates. Eleven patients became non-frail after 6 months of the combined treatment, and their improvement rate was 78.6%. The aforementioned combination therapy not only improved dizziness but also improved frailty. Following 6 months of combined treatment, patients in the frailty group exhibited improvement in the Dizziness Handicap Inventory score, frailty symptoms, Kihon checklist score, and visual analog scale score (fatigue), and approached the pre-treatment values of those in the non-frailty group. Together, our results highlight the need to combine the treatment for intractable dizziness and frailty.

患有慢性顽固性头晕（以下简称“顽固性头晕”）的患者发生虚弱并发症的风险很高。这需要对顽固性头晕和虚弱的联合治疗进行调查。Ninjin'yoeito (NYT)，一种日本传统医学（汉方药），据报道可有效治疗虚弱和肌肉减少症。在此，我们报告一项回顾性研究的结果，该研究涉及联合应用《纽约时报》和头晕康复治疗（以下简称“头晕康复”）。31例顽固性头晕患者中，14例出现虚弱，并发症发生率为45.2%。这反过来又比先前报告的比率高出大约 4 倍。11例患者联合治疗6个月后不再体弱，好转率为78.6%。上述联合疗法不仅改善了头晕，而且改善了虚弱。经过 6 个月的联合治疗，虚弱组患者的头晕障碍量表评分、虚弱症状、Kihon 检查表评分、和视觉模拟量表评分（疲劳），并接近非虚弱组患者的治疗前值。总之，我们的结果强调需要结合治疗顽固性头晕和虚弱。